In vitro evaluation of gentamicin- and vancomycin-containing minitablets as a replacement for fortified eye drops

References

• Garg P, Sharma S, Rao GN. (1999). Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology, 106:1319–23.
   PubMed Web of Science ®Google Scholar
• Goldstein HM, Kowalski PR, Gordon YJ. (1999). Emerging fluoroquinolone resistance in bacterial keratitis. Ophthalmology, 106:1313–8.
   PubMed Web of Science ®Google Scholar
• Foster CS, Azar D, Dohlman CH. (2005). The cornea: Scientific foundations and clinical practice. Philadelphia, USA: Lippincott Williams & Wilkins.
   Google Scholar
• Allan BD, Dart JKG. (1995). Strategies for the management of microbial keratitis. Br J Ophthalmol, 79:777–86.
   PubMed Web of Science ®Google Scholar
• Weyenberg W, Vermeire A, Dhondt MMM, Adriens E, Kestelyn P, Remon JP, . (2004). Ocular bioerodible minitablets as a strategy for the management of microbial keratitis. Invest Ophthalmol Vis Sci, 45:3229–33.
   PubMed Web of Science ®Google Scholar
• Wilhelmus KR. (1996). Bacterial keratitis. In: Jay S, ed. Ocular infection and immunity. Saint Louis (MO): CV Mosby, 985–95.
   Google Scholar
• Pflugfelder SC, Hernandez E, Fliesler SJ. (1987). Intravitreal vancomycin: Retinal toxicity, clearance, and interaction with gentamicin. Arch Ophthalmol, 105:831–7.
   PubMed Web of Science ®Google Scholar
• Posyniak A, Zmudzki J, Niedzielska J. (2001). Sample preparation for residue determination of gentamicin and neomycin by liquid chromatography. J Chromatogr A, 914:59–66.
   PubMed Web of Science ®Google Scholar
• Ruszczak Z, Friess W. (2003). Collagen as a carrier for on-site delivery of bacterial drugs. Adv Drug Deliv Rev, 55:1679–98.
   PubMed Web of Science ®Google Scholar
• Chen HY, Williams JD. (1984). The activity of vancomycin and teicoplanin alone and in combination with gentamicin or ampicillin against Streptococcus faecalis. Eur J Clin Microbiol, 3:436–8.
   PubMedGoogle Scholar
• Lam K, Bayer AS. (1984). In vitro bactericidal synergy of gentamicin combined with penicillin G, vancomycin, or defotaxime against group G streptococci. Antimicrob Agents Chemother, 26:260–2.
   PubMed Web of Science ®Google Scholar
• Lowy FD, Chang DS, Lash PR. (1983). Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci. Antimicrob Agents Chemother, 23:932–5.
   PubMed Web of Science ®Google Scholar
• Zervos MJ, Dembinski S, Mikesell T. (1986). High-level resistance to gentamicin in Streptococcus faecalis: Risk factors and evidence for exogenous acquisition of infection. J Infect Dis, 153:1075–83.
   PubMed Web of Science ®Google Scholar
• Lee VHL, Robinson JR. (1986). Topical ocular drug delivery: Recent developments and future challenges. J Ocul Pharmacol, 2:67–108.
   PubMedGoogle Scholar
• Diamond J. (1997). Systemic adverse effects of topical ophthalmic agents. Implications for older patients. Drugs Aging, 11:352–60.
   PubMed Web of Science ®Google Scholar
• Doona M, Walsh J. (1995). Use of chloramphenicol as topical medication: Time to cry halt? Br Med J, 310:1217–8.
   PubMedGoogle Scholar
• Flach A. (1994). Systemic toxicity associated with ophthalmic medications. J Fla Med Assoc, 81:256–60.
   PubMedGoogle Scholar
• Salminen L. (1990). Review. Systemic absorption of topically applied ocular drugs in humans. J Ocul Pharmacol, 6:243–9.
   PubMedGoogle Scholar
• Baudouin C. (1996). Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol, 7:80–6.
   PubMedGoogle Scholar
• Topalkara A, Güler C, Arıcı MK. (2000). Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Exp Ophthalmol, 28:113–7.
   PubMed Web of Science ®Google Scholar
• Gurtler F, Kaltsatos V, Boisramé B. (1995). Ocular availability of gentamicin in small animals after topical administration of a conventional eye drop solution and a novel long acting bioadhesive ophthalmic drug insert. Pharm Res, 12:1791–5.
   PubMed Web of Science ®Google Scholar
• Ludwig A. (2005). The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev, 57:1595–639.
   PubMed Web of Science ®Google Scholar
• Ceulemans J, Vermeire A, Adriaens E, Remon JP, Ludwig A. (2001). Evaluation of a mucoadhesive tablet for ocular use. J Control Release, 77:333–44.
   PubMed Web of Science ®Google Scholar
• Weyenberg W, Vermeire A, Remon JP, Ludwig A. (2003). Characterization and in vivo evaluation of ocular bioadhesive minitablets compressed at different forces. J Control Release, 89:329–40.
   PubMed Web of Science ®Google Scholar
• Weyenberg W, Vermeire A, D’Haese E, Vanhaelewyn G, Kestelyn P, Callens F, . (2004). Effect of different sterilisation methods on the properties of bioadhesive powders and ocular minitablets, and clinical evaluation. Eur J Pharm Sci, 23:77–87.
   PubMed Web of Science ®Google Scholar
• Choonara YE, Pillay V, Carmichael T, Danckwerts MP. (2006). An in vitro study of the design and development of a novel doughnut-shaped minitablet for intraocular implantation. Int J Pharm, 310:15–24.
   PubMed Web of Science ®Google Scholar
• Choonara YE, Pillay V, Carmichael T, Danckwerts MP. (2007). Studies on a novel doughnut-shaped minitablet for intraocular drug delivery. AAPS PharmSciTech, 8:E118.
   PubMedGoogle Scholar
• Van Haeringen NJ. (1981). Clinical biochemistry of tears. Surv Ophthalmol, 5:84–96.
   Google Scholar
• European Pharmacopoeia, 6th ed. (2008). Strasbourg (France): Council of Europe.
   Google Scholar
• Adriaens E, Dhondt MM, Remon JP. (2005). Refinement of the Slug Mucosal Irritation test as an alternative screening test for eye irritation. Toxicol In Vitro, 19:79–89.
   PubMed Web of Science ®Google Scholar
• Adriaens E, Remon JP. (1999). Gastropods as an evaluation tool for screening the irritating potency of absorption enhancers and drugs. Pharm Res, 16:1240–4.
   PubMed Web of Science ®Google Scholar
• Adriaens E, Ameye D, Dhondt M, Foreman P, Remon JP. (2003). Evaluation of the mucosal irritation potency of co-spray dried Amioca®/poly(acrylic acid) and Amioca®/Carbopol® 974P mixtures. J Control Release, 88:393–9.
   PubMed Web of Science ®Google Scholar
• Callens C, Adriaens E, Dierckens K, Remon JP. (2001). Toxicological evaluation of a bioadhesive nasal powder containing a starch and Carbopol 974 P on rabbit nasal mucosa and slug mucosa. J Control Release, 76:81–91.
   PubMed Web of Science ®Google Scholar
• Adriaens E, Dhondt M, Remon JP. (2004). Applications of the Slug Mucosal Irritation test. InVitox-2004, Poland (poster presentation).
   Google Scholar
• Diana J, Visky D, Hoogmartens J, Van Schepdael A, Adams E. (2006). Investigation of vancomycin and related substances by liquid chromatography/ion trap mass spectrometry. Rapid Commun Mass Spectrom, 20:685–93.
   PubMed Web of Science ®Google Scholar
• Haghedooren E, Diana J, Noszal B, Hoogmartens J, Adams E. (2007). Classification of reversed-phase columns based on their selectivity towards vancomycin compounds. Talanta, 71:31–7.
   PubMed Web of Science ®Google Scholar
• Sebhatu T, Angberg M, Ahlneck C. (1994). Assessment of the degree of disorder in crystalline solids. Int J Pharm, 101:237–47.
   Web of Science ®Google Scholar
• Weyenberg W, Bozdag S, Foreman P, Remon JP, Ludwig A. (2006). Characterization and in vivo evaluation of ocular minitablets prepared with different bioadhesive Carbopol-starch components. Eur J Pharm Biopharm, 62:202–9.
   PubMed Web of Science ®Google Scholar
• Gohel MC, Parikh RK, Padshala MN, Sarvaiya KG, Jena DG. (2007). Formulation and optimization of directly compressible isoniazid modified release matrix tablet. Ind J Pharm Sci, 69:640–5.
   Google Scholar
• Bozdag S, Weyenberg W, Ludwig A. (2005). Rheological evaluation of dispersions, prepared with different non- and gamma-irradiated bioadhesive cospray-dried powder mixtures. Pharmazie, 60:593–7.
   PubMed Web of Science ®Google Scholar
• Phinney RB, Schwartz S, Lee DA, Mondino BJ. (1988). Collagen-shield delivery of gentamicin and vancomycin. Arch Ophthalmol, 106:1599–604.
   PubMed Web of Science ®Google Scholar
• ICH. (2006). Note for guidance on impurities in new drug products (CPMP/ICH/2738/99). ICH Topic Q 3B (R2) Impurities in New Drug Products.
   Google Scholar
• Bartolotta A, D’Oca MC, Campisi M, De Caro V, Giandalia G, Giannola LI, . (2005). Effects of gamma-irradiation on thehalose-hydroxyethylcellulose microspheres loaded with vancomycin. Eur J Pharm Biopharm, 59:139–46.
   PubMed Web of Science ®Google Scholar